Biosimilars Deals 2020

20 Aug 2020 | Intract Pharma, Celltrion | Intract Pharma and Celltrion announce an agreement to jointly develop the world's first oral antibody therapeutic for the treatment of IBD. The infliximab product has been cleared by the UK's MHRA to proceed to Ph 1b/2a clinical trials in patients with IBD during the second half of 2021.


05 Aug 2020 | Alvotech, Teva | Alvotech and Teva announce a strategic partnership to collaborate on five biosimilar product candidates in the US market. Under the agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercialising the products in the US. The agreement includes an upfront payment, with subsequent milestone payments, with Alvotech and Teva to share the profits from commercialisation.


17 Jul 2020 | VentureTECH, Duopharma and PanGen | VentureTECH, Duopharma and PanGen Biotech announce a joint venture to develop a Malaysian biosimilar production facility.


17 Jul 2020 | Bio-Thera Solutions, Pharmapark | Bio-Thera Solutions annnounces a licensing agreement with Pharmapark for BAT2506 (biosimilar golimumab candidate). Under the agreement, Pharmapark will have exclusive rights to distribute and market the drug in Russia and other CIS countries.


25 June 2020 | AbbVie, Sosei Heptares | Abbvie and Sosei Heptares announce a $409M deal to discover and develop new immunology drugs.  The agreement covers the drug-discovery, development and commercialisation of small-molecule medicines that target autoimmune and inflammatory diseases using the G protein-coupled receptor.  AbbVie will pay Sosei Heptares up to $32M upfront and at milestones for an additional $377M, along with royalties.


11 June 2020 | Celltrion, Takeda | Celltrion announces a $278 million deal to acquire Takeda Pharmaceuticals Primary Care businesses in the Asia Pacific. Under the agreement, Celltrion will gain access to patent, trademark and marketing rights for 18 prescription and over-the-counter brands in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Singapore and Australia.


08 May 2020 | AbbVie, Allergan | AbbVie announces it has completed its acquisition of Allergan, following regulatory approval from all relevant Government agencies. AbbVie will now have access to Allergan's neuroscience products including Vraylar® and Ubrelvy®, and aesthetic products including the Botox® and Juvederm® brands.


15 Jan 2020 | Alvotech, JAMP Pharma | Alvotech and JAMP announce agreement to commercialise five biosimilar products in Canada.


13 Jan 2020 | Mundipharma, Samsung | Mundipharma announces commercialisation agreement with Samsung. The agreement grants Mundipharma exclusive commercialisation rights to Samsung's adalimumab, etanercept, trastuzumab and bevacizumab candidates in Taiwan and Hong Kong.







Share on Facebook
Share on Twitter
Please reload

Biosimilars Bulletin 

August 19, 2020

Please reload

Search by tags